Liquid Biopsy Testing for Lung Cancer
Trial Summary
The trial information does not specify if you need to stop your current medications. It focuses on patients already receiving certain immune therapies, so you might be able to continue those treatments.
Research shows that PD-L1 expression in circulating tumor cells can help identify lung cancer patients who might respond to immunotherapy, offering a non-invasive way to guide treatment decisions.
12345The research does not provide specific safety data for liquid biopsy testing in humans, but it does mention that PD-L1 testing, which is part of the liquid biopsy process, is commonly used in lung cancer care, suggesting it is generally considered safe.
16789Liquid biopsy testing for lung cancer is unique because it uses a blood test to analyze circulating tumor cells for PD-L1 expression, which can help determine the best treatment options. This method is less invasive than traditional tissue biopsies and can provide a more comprehensive view of the tumor's characteristics, potentially leading to more personalized and effective treatment plans.
124510Eligibility Criteria
This trial is for individuals with lung cancer, specifically non-small cell lung cancer, who are undergoing treatment with immune checkpoint inhibitors. Participants will have their blood tested to monitor changes in a specific RNA linked to the body's response to therapy.Inclusion Criteria
Exclusion Criteria